Skip to content

Evaluation and Management of Cardiovascular Risk Factors in Inflammatory and Acquired Dysimmune Diseases (CARMIN)

Evaluation and Management of Cardiovascular Risk Factors in Inflammatory and Acquired Dysimmune Diseases (CARMIN)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02835547
Acronym
CARMIN
Enrollment
600
Registered
2016-07-18
Start date
2009-02-28
Completion date
2015-08-31
Last updated
2016-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory and Acquired Dysimmune Diseases

Keywords

cardiovascular event, risk factors, inflammatory diseases and acquired dysimmune

Brief summary

The hypothesis is that chronic inflammatory dysimmune state promotes the development of cardiovascular complications. The biological assumption is based on the fact that chronic inflammation promotes lesions of the vessel wall (endothelial alterations, calcification, atherosclerosis). The clinical aim is to allow to identify high-risk patients and to act in prevention. The project CARMIN involves the assessment of cardiovascular risk factors, their management, and their influence on cardiovascular prognosis in patients with autoimmune diseases and immunodeficiencies acquired. It is based on the creation and monitoring of a cohort of patients with different types of dysimmune disorders: systemic lupus erythematosus, rheumatoid arthritis, psoriasis, scleroderma, systemic vasculitis ANCA, kidney transplants, and hematopoietic stem cells transplants.

Interventions

OTHERData collection

Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients followed in the various services of medical specialties pole of the Edouard Herriot hospital * The diagnosis of the pathology selected for this study based on a clear clinical and biological evaluation supported by criteria specific to each pathology and compatible with international standards. * Date of diagnosis should not be less than 5 years (+/- 1 year), except for scleroderma patients where it has been extended to 10 years. * For kidney transplant patients the investigators take into account only patients with a maximum of 2 years of dialysis before graft.

Exclusion criteria

* Diabetic patients * HIV seropositive * Patients with multiple pathologies

Design outcomes

Primary

MeasureTime frameDescription
The occurrence of any cardiovascular event (will be recorded from the patient files and/or phone calls to patient)2 yearsThe cardiovascular events : cardiovascular death, myocardial infarction, stroke, peripheral arterial disease, ischemic manifestations in other territories, heart failure, arrhythmia, deep vein thrombosis or pulmonary embolism.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026